CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting CALQUENCE plus venetoclax ...
Calquence plus Venclexta, with or without Gazyva, significantly improved progression-free and overall survival in untreated CLL patients compared to chemoimmunotherapy. The study showed a higher ...
What Is It, and Why Does It Matter? The FDA has approved a new combination treatment for adults with certain cancers of the blood and lymphatic system. The targeted regimen combines Calquence ...
Findings showed acalabrutinib with bendamustine and rituximab (BR) reduced the risk of disease progression or death by 27% compared with placebo plus BR. Findings showed acalabrutinib with BR reduced ...
AstraZeneca has secured a key regulatory win in its effort to reclaim the lead in the BTK inhibitor market, with the FDA approving its combination of Calquence plus Venclexta as the first all-oral, ...
Hosted on MSN
FDA approval for AbbVie/AstraZeneca's combination treatment could set new standard for slow growing blood cancer
On Friday, the U.S. Food and Drug Administration (FDA) approved AbbVie Inc.'s ABBV combination treatment for chronic lymphocytic leukemia (CLL). The FDA has approved the combination of Venclexta ...
Ontario is the first province to fund Tagrisso for patients with non-small cell lung cancer, and Calquence for patients with previously untreated mantle cell lymphoma MISSISSAUGA, ON, Jan. 23, 2026 ...
AMPLIFY showed improved PFS for acalabrutinib/venetoclax versus FCR or BR, with HR 0.65 and median PFS not estimable versus 47.6 months at 42.6-month follow-up ...
CLL is the most common type of leukemia in adults. 3 An estimated 18,500 people were treated for CLL in the 1st-line setting in the US in 2024. 4 Jennifer Brown, MD, PhD, Director of the CLL Center of ...
Findings showed acalabrutinib with bendamustine and rituximab (BR) reduced the risk of disease progression or death by 27% compared with placebo plus BR. The Food and Drug Administration (FDA) has ...
CALQUENCE plus venetoclax demonstrated statistically significant and clinically meaningful improvement in progression-free survival vs. chemoimmunotherapy, with 77% of patients progression free at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results